1. Risk Stratification in PAH: What Do the Latest Data Suggest?

3. Registry Studies

4. 2015 ESC/ERS Guidelines Risk Assessment in PAH

5. French PH Registry Low-Risk Criteria

6. French PH Registry Baseline Characteristics

7. French PH Registry Number of Low-Risk Criteria Achieved and Survival

8. French PH Registry Number of Noninvasive Low-Risk Criteria Achieved and Survival

9. French PH Registry Take-Home Message

10. COMPERA Registry Risk Stratification

11. COMPERA Registry Baseline Characteristics

12. COMPERA Registry 1-Year Mortality

13. COMPERA Registry Take-Home Messages

14. SPAHR Risk Stratification

15. SPAHR 5-Year Survival

16. SPAHR Change in Risk Group at Follow-Up and 5-Year Survival

17. SPAHR Take-Home Messages

18. REVEAL Registry PAH Risk Score

19. REVEAL Registry Updated PAH Risk Score

20. Need for Early Diagnosis and Intensification of Disease Management

21. Monotherapy Is Frequently Inadequate

22. PAH Population Is Heterogeneous

23. French PH Registry Early Combination Treatment Leads to Better Long-Term Survival

24. Role of PAH Centers

25. Multidisciplinary Approach to PAH Management

26. Place of Lung Transplantation in PAH Management

27. Summary

28. Abbreviations

29. Abbreviations (cont)